BioWorld Asia

Feb. 21, 2007

Bavarian Nordic Raising $82M In Discounted Rights Offering

Bavarian Nordic A/S is set to raise gross proceeds of DKK465 million (US$82 million) from a fully underwritten rights issue directed at current shareholders. (BioWorld International) Read More

Ark Gets OKs To Advance Vitor Into Phase III Studies

Receptor May Hold Key To Treating Myeloma

Basilea Pharma Hits New High On Alitretinoin Phase III Data

Celogos Licenses Myoblast Tool For Stress Urinary Incontinence

Other News To Note

CeNeS Pain Compound Shows Good Results, With One Glitch

New French Biosimilar Controls Get Warm Welcome In Europe

EU Launches Study To Boost Biotech Competitiveness

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...